Compounded GLP-1s after the crackdown: what is actually legal in mid-2026
Every deadline has passed, and the market is still here. That is not proof of legality — and not proof of illegality either. The truth runs through one exception.
Since the FDA declared the tirzepatide shortage resolved (December 2024) and semaglutide resolved (February 2025), compounding copies of the brand products is no longer permitted under the shortage exception; 503A pharmacies had to stop by February–April 2025 and 503B facilities by March–May 2025. What remains legal is narrow: compounding that produces a genuinely different formulation for a documented individual clinical need — a different dose, combination or form a prescriber justifies per patient. Programs selling standard-dose copies at scale are operating in the enforcement zone; programs built on documented personalization occupy a contested but defensible space the courts have so far left standing.
- How we got here: The legal foundation of the compounded GLP-1 boom was drug-shortage law: when the FDA lists a drug as in shortage, compounders may produce what are....
- The personalization exception, precisely stated: Compounding law never prohibited compounding as such — it prohibits producing what is “essentially a copy” of a commercially available drug.
- What the surviving market actually looks like: Mid-2026 compounded programs cluster into three postures.
- What enforcement has and has not done: The FDA's 2025–2026 actions concentrated on the clearest violations: salt-form semaglutide, “research use only” sellers, unregistered facilities, a....
- What this means if you are a patient on it: Possessing and using compounded medication prescribed to you is not, and has never been, the legal exposure — enforcement targets producers and pre....
How we got here: the shortage era and its end
The legal foundation of the compounded GLP-1 boom was drug-shortage law: when the FDA lists a drug as in shortage, compounders may produce what are essentially copies. Tirzepatide entered the shortage list in 2022 and left it on December 19, 2024; semaglutide followed, resolved February 21, 2025. With resolution came wind-down deadlines — 503A pharmacies had to cease copies of tirzepatide by February 18, 2025 and semaglutide by April 22, 2025; 503B outsourcing facilities by March 19 and May 22, 2025 respectively.
The compounding trade association sued to reverse both shortage determinations; the courts declined to block enforcement. That litigation's failure is why mid-2025 became the pivot point — and why every compounded program you see in July 2026 rests on something other than the shortage exception.
| Activity | Status | Basis |
|---|---|---|
| Copies during shortage | Ended | Shortages resolved Dec 2024 / Feb 2025 |
| Standard-dose copies now | Prohibited | FD&C ‘essentially a copy’ bar; deadlines passed 2025 |
| Documented individualized formulation | Permitted, contested edges | Per-patient prescriber determination |
| Salt-form semaglutide | Prohibited | FDA: salts don’t qualify for compounding |
| ‘Research-use’ no-Rx sales | Illegal | No prescription, no pharmacy chain |
The personalization exception, precisely stated
Compounding law never prohibited compounding as such — it prohibits producing what is “essentially a copy” of a commercially available drug. A compounded product is not a copy when a prescriber determines, for an identified individual patient, that a change matters clinically: a dose the brand does not make, removal of an ingredient the patient cannot tolerate, a combination, or a different administration form with clinical justification.
That word — individual — is the entire battleground. A prescriber documenting why one patient needs 3.75 mg when brand pens jump from 2.5 to 5 is squarely inside the exception. A telehealth platform whose every patient somehow needs the identical “personalized” dose with an identical additive is running a copy business wearing the exception as a costume, and FDA warning letters through 2025–2026 have targeted exactly that pattern.
What the surviving market actually looks like
Mid-2026 compounded programs cluster into three postures. Documented-personalization programs: non-standard doses, prescriber notes articulating individual rationale, named pharmacies — the defensible tier. Microdose programs: sub-brand doses marketed as titration flexibility, a posture whose legitimacy depends entirely on whether the individualized rationale is real (our microdose legal-loophole article dissects this). And copy-at-scale operations: standard brand-equivalent doses, template “personalization,” often anonymous pharmacies — the tier absorbing warning letters and state board actions.
Pricing tracks posture. The verified floor for compliant-posture tirzepatide programs sits around $147–$199 per month; operations undercutting that dramatically are usually cutting the compliance, the pharmacy, or the drug itself — the counterfeit guide's territory.
What enforcement has and has not done
The FDA's 2025–2026 actions concentrated on the clearest violations: salt-form semaglutide, “research use only” sellers, unregistered facilities, and platforms whose personalization was demonstrably templated. State pharmacy boards — who license the pharmacies — have been the more active enforcers in several states, and state telehealth rules add a second compliance layer that varies by patient location (our state pages track this).
What has not happened: a categorical ban on GLP-1 compounding, or mass enforcement against genuinely individualized prescribing. The agency's own statements distinguish copies from personalization; the gray zone persists because that line is drawn per prescription, not per company. Patients should read “the FDA shut down compounded semaglutide” headlines and “compounding is fully legal” marketing with equal suspicion — both flatten a per-prescription question into a slogan.
What this means if you are a patient on it
Possessing and using compounded medication prescribed to you is not, and has never been, the legal exposure — enforcement targets producers and prescriber platforms. Your risks are practical: supply interruption if your program receives an action, and product quality if your program's compliance posture is thin. Both are testable with three questions: What is the individualized clinical rationale documented in my file for this formulation? Which pharmacy fills it, and is its license current? What happens to my supply and my records if the program stops operating?
A program that answers all three in writing sits in the market's defensible tier. One that answers none is asking you to carry its regulatory risk at $200 a month. And the brand alternative math has changed: with a $149 approved oral, $199–$349 injectable starters and the Medicare Bridge pilot, the price gap that justified marginal programs has narrowed to the point where the compliant tier is the only tier worth using.
Frequently asked questions
Can I get in trouble for using compounded semaglutide?
Enforcement targets producers and platforms, not patients. Your practical risks are supply interruption and product quality, which is why the three verification questions in this article matter more than the headlines.
Is microdosed compounded tirzepatide legal?
It depends on whether the sub-brand dose reflects a documented individual clinical rationale or a marketing template applied to everyone. The formulation being non-standard is necessary but not sufficient.
Will compounded GLP-1s disappear?
The copy-at-scale tier is shrinking under enforcement and under brand price competition. The individualized tier has survived every legal challenge so far and is likely to persist as a smaller, higher-compliance market.